: Rated as a top pick by Morningstar , trading roughly 7% below its fair value with a 3.62% forward yield.
: Despite valuation concerns, analysts at CFRA see a 35% upside due to accelerating AI adoption and margin expansion. which company is best to buy shares
: Recognized by Morningstar as "undervalued" with a wide economic moat, trading at about 60% of its fair value. : Rated as a top pick by Morningstar
These companies are leading in rapidly expanding sectors like artificial intelligence (AI) and biotechnology. in Saudi Arabia and Europe.
: This biotech firm has surged nearly 394% year-to-date following the commercial launch of its cancer drug, Anktiva, in Saudi Arabia and Europe.